studies

mNSCLC - L1 - PDL1 positive, pembrolizumab alone vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.60 [0.41; 0.88] KEYNOTE-042 (PDL1>1%), 2019 0.81 [0.71; 0.93] KEYNOTE-042 (PDL1>20%), 2019 0.77 [0.64; 0.92] KEYNOTE-042 (PDL1>50%), 2019 0.69 [0.56; 0.85] KEYNOTE-598, 2020 1.08 [0.85; 1.37] 0.79[0.68; 0.92]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-598, 2020561%3,564moderatenot evaluable deaths (OS) (extension)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.62 [0.48; 0.81] KEYNOTE-042 (PDL1>1%), 2019 0.80 [0.71; 0.90] KEYNOTE-042 (PDL1>20%), 2019 0.75 [0.64; 0.88] KEYNOTE-042 (PDL1>50%), 2019 0.98 [0.82; 1.18] 0.79[0.68; 0.92]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019467%2,996moderatenot evaluable PFS (extension)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.50 [0.39; 0.65] KEYNOTE-042 (PDL1>1%), 2019 1.05 [0.93; 1.18] KEYNOTE-042 (PDL1>20%), 2019 0.95 [0.82; 1.10] KEYNOTE-042 (PDL1>50%), 2019 0.85 [0.71; 1.01] 0.82[0.64; 1.06]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019489%2,996moderatenot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.50 [0.37; 0.68] KEYNOTE-042 (PDL1>1%), 2019 1.07 [0.94; 1.21] KEYNOTE-042 (PDL1>20%), 2019 0.94 [0.80; 1.11] KEYNOTE-042 (PDL1>50%), 2019 0.81 [0.67; 0.98] KEYNOTE-598, 2020 1.06 [0.86; 1.30] 0.87[0.71; 1.07]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-598, 2020583%3,564moderateserious objective responses (ORR)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 2.11 [1.31; 3.39] KEYNOTE-042 (PDL1>1%), 2019 1.04 [0.81; 1.33] KEYNOTE-042 (PDL1>20%), 2019 1.24 [0.92; 1.66] KEYNOTE-042 (PDL1>50%), 2019 1.39 [0.99; 1.94] KEYNOTE-598, 2020 1.00 [0.72; 1.39] 1.24[1.01; 1.54]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-598, 2020553%3,564moderateserious objective responses (ORR) (extension)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 1.89 [1.19; 3.02] KEYNOTE-042 (PDL1>1%), 2019 1.03 [0.81; 1.32] KEYNOTE-042 (PDL1>20%), 2019 1.21 [0.90; 1.62] KEYNOTE-042 (PDL1>50%), 2019 1.35 [0.96; 1.88] 1.26[1.02; 1.57]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019445%2,996moderatenot evaluable STRAE (any grade)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 1.05 [0.60; 1.82] 1.05[0.60; 1.82]KEYNOTE-024 (PDL1>50%), 201610%304NAnot evaluable STRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.55; 1.72] 0.97[0.55; 1.72]KEYNOTE-024 (PDL1>50%), 201610%304NAnot evaluable TRAE (any grade)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.31 [0.16; 0.58] KEYNOTE-042 (PDL1>1%), 2019 0.19 [0.14; 0.26] 0.22[0.14; 0.34]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019244%1,555moderatenot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.32 [0.20; 0.51] KEYNOTE-042 (PDL1>1%), 2019 0.30 [0.23; 0.39] 0.30[0.24; 0.38]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.32 [0.03; 3.11] KEYNOTE-042 (PDL1>1%), 2019 0.90 [0.42; 1.92] 0.81[0.39; 1.66]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable TRAE leading to discontinuation (any grade)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.64 [0.29; 1.44] KEYNOTE-042 (PDL1>1%), 2019 0.95 [0.64; 1.39] 0.88[0.62; 1.24]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.86 [0.32; 2.29] KEYNOTE-042 (PDL1>1%), 2019 1.09 [0.71; 1.66] 1.05[0.71; 1.55]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15] 3.88[0.17; 86.15]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21] 0.07[0.00; 1.21]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.08 [0.02; 0.28] KEYNOTE-042 (PDL1>1%), 2019 0.04 [0.02; 0.12] 0.06[0.03; 0.12]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Arthralgia TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81] 0.97[0.02; 48.81]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 0.29 [0.08; 1.05] 0.29[0.08; 1.05]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Blood creatinine increased TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.49 [0.02; 14.58] 0.49[0.02; 14.58]KEYNOTE-024 (PDL1>50%), 201610%304NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 3.93 [0.18; 87.97] KEYNOTE-042 (PDL1>1%), 2019 3.89 [0.43; 34.87] 3.90[0.65; 23.43]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81] 0.97[0.06; 15.56]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.12 [0.01; 2.27] KEYNOTE-042 (PDL1>1%), 2019 0.53 [0.18; 1.60] 0.44[0.16; 1.24]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Diabetes TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69] 1.95[0.07; 58.69]KEYNOTE-024 (PDL1>50%), 201610%304NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 3.00 [0.60; 15.11] KEYNOTE-042 (PDL1>1%), 2019 4.87 [0.57; 41.77] 3.57[0.98; 13.00]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Dysgeusia TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] 0.97[0.02; 49.41]KEYNOTE-024 (PDL1>50%), 201610%304NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.38 [0.07; 2.00] KEYNOTE-042 (PDL1>1%), 2019 0.36 [0.09; 1.36] 0.37[0.13; 1.04]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Hepatitis TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 13.68 [0.77; 241.54] 13.68[0.77; 241.54]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80] 1.44[0.11; 18.83]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69] KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52] 3.62[0.38; 34.25]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80] 1.44[0.11; 18.83]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Increase AST TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 1.94 [0.35; 10.63] 1.94[0.35; 10.63]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 1.75 [0.58; 5.26] 1.75[0.58; 5.26]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] KEYNOTE-042 (PDL1>1%), 2019 0.16 [0.02; 1.33] 0.24[0.04; 1.55]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 0.05 [0.00; 0.82] 0.05[0.00; 0.82]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Myalgia TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80] 1.94[0.06; 57.80]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Myocarditis TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80] 1.94[0.06; 57.80]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] 0.97[0.02; 49.41]KEYNOTE-024 (PDL1>50%), 201610%304NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.16 [0.01; 3.21] KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21] 0.10[0.01; 0.82]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Nephritis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69] KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80] 1.94[0.18; 21.52]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.02 [0.00; 0.35] KEYNOTE-042 (PDL1>1%), 2019 0.02 [0.00; 0.14] 0.02[0.00; 0.10]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69] KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81] 1.44[0.11; 18.87]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Peripheral neuropathy TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 1.76] 0.10[0.01; 1.76]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 0.08 [0.00; 1.43] 0.08[0.00; 1.43]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 3.97 [0.44; 35.97] KEYNOTE-042 (PDL1>1%), 2019 20.97 [2.81; 156.36] 9.73[1.92; 49.42]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019216%1,555moderatenot evaluable Pruritus TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15] 3.88[0.17; 86.15]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] 0.97[0.02; 49.41]KEYNOTE-024 (PDL1>50%), 201610%304NAnot evaluable Rash TRAE (grade 3-4)detailed resultsKEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52] 5.82[0.29; 116.52]KEYNOTE-042 (PDL1>1%), 201910%1,251NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 12.12 [0.67; 218.98] KEYNOTE-042 (PDL1>1%), 2019 10.81 [1.39; 83.96] 11.23[2.11; 59.83]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Stomatitis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.24 [0.01; 5.39] KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81] 0.41[0.04; 4.70]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.06 [0.00; 1.02] KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 0.75] 0.08[0.02; 0.43]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41] KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81] 0.97[0.06; 15.56]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Vomiting TRAE (grade 3-4)detailed resultsKEYNOTE-024 (PDL1>50%), 2016 0.97 [0.06; 15.71] KEYNOTE-042 (PDL1>1%), 2019 0.24 [0.01; 5.36] 0.52[0.07; 4.14]KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 201920%1,555moderatenot evaluable Anaemia AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 1.14 [0.41; 3.20] 1.14[0.41; 3.20]KEYNOTE-598, 202010%563NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 2.01 [0.36; 11.05] 2.01[0.36; 11.05]KEYNOTE-598, 202010%563NAnot evaluable Asthenia AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 0.25 [0.03; 2.22] 0.25[0.03; 2.22]KEYNOTE-598, 202010%563NAnot evaluable Back pain AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 0.50 [0.04; 5.51] 0.50[0.04; 5.51]KEYNOTE-598, 202010%563NAnot evaluable Constipation AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 1.00 [0.14; 7.12] 1.00[0.14; 7.12]KEYNOTE-598, 202010%563NAnot evaluable Cough AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 0.50 [0.02; 14.89] 0.50[0.02; 14.89]KEYNOTE-598, 202010%563NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 6.03 [0.30; 120.98] 6.03[0.30; 120.98]KEYNOTE-598, 202010%563NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 10.29 [1.31; 80.96] 10.29[1.31; 80.96]KEYNOTE-598, 202010%563NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 0.87 [0.31; 2.43] 0.87[0.31; 2.43]KEYNOTE-598, 202010%563NAnot evaluable Fatigue AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 1.51 [0.42; 5.39] 1.51[0.42; 5.39]KEYNOTE-598, 202010%563NAnot evaluable Hypothyroidism AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 1.00 [0.06; 16.01] 1.00[0.06; 16.01]KEYNOTE-598, 202010%563NAnot evaluable Increase AST AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 2.52 [0.48; 13.09] 2.52[0.48; 13.09]KEYNOTE-598, 202010%563NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 2.28 [0.69; 7.50] 2.28[0.69; 7.50]KEYNOTE-598, 202010%563NAnot evaluable Nausea AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 4.01 [0.18; 89.26] 4.01[0.18; 89.26]KEYNOTE-598, 202010%563NAnot evaluable Pneumonia AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 1.36 [0.72; 2.56] 1.36[0.72; 2.56]KEYNOTE-598, 202010%563NAnot evaluable Pneumonitis AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 2.21 [0.83; 5.91] 2.21[0.83; 5.91]KEYNOTE-598, 202010%563NAnot evaluable Pruritus AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 0.50 [0.04; 5.51] 0.50[0.04; 5.51]KEYNOTE-598, 202010%563NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 6.03 [0.30; 120.98] 6.03[0.30; 120.98]KEYNOTE-598, 202010%563NAnot evaluable Rash AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 16.38 [0.94; 286.59] 16.38[0.94; 286.59]KEYNOTE-598, 202010%563NAnot evaluable Vomiting AE (grade 3-4)detailed resultsKEYNOTE-598, 2020 4.03 [0.45; 36.27] 4.03[0.45; 36.27]KEYNOTE-598, 202010%563NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-05-14 18:48 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 171 - treatments: 359,575,577,576,869

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons